90240

Glyceryl triacetate

≥99.0% (GC)

• Synonim(y): 1,2,3-Triacetoxypropane, 1,2,3-Triacetylglycerol, Glycerol triacetate, Triacetin
• Wzór liniowy: (CH₃COOCH₂)₂CHOCOCH₃
• Numer CAS: 102-76-1
• Masa cząsteczkowa: 218.20
• UNSPSC Code: 12352211
• NACRES: NA.25
• PubChem Substance ID: 329769862
• EC Number: 203-051-9
• Beilstein/REAXYS Number: 1792353
• MDL number: MFCD00008716
• Assay: ≥99.0% (GC)
• Form: liquid

Właściwości

• Quality Segment: 200
• assay: ≥99.0% (GC)
• form: liquid
• greener alternative product characteristics: Less Hazardous Chemical Syntheses; Learn more about the Principles of Green Chemistry.
• sustainability: Greener Alternative Product
• refractive index: n20/D 1.431
• bp: 258-260 °C (lit.)
• density: 1.158 g/mL at 20 °C
• greener alternative category: Aligned
• lipid type: saturated FAs
• SMILES string: CC(=O)OCC(COC(C)=O)OC(C)=O
• InChI: 1S/C9H14O6/c1-6(10)13-4-9(15-8(3)12)5-14-7(2)11/h9H,4-5H2,1-3H3
• InChI key: URAYPUMNDPQOKB-UHFFFAOYSA-N

Opis

General description

We are committed to bringing you Greener Alternative Products, which adhere to one or more of The 12 Principles of Green Chemistry. This product can replace highly toxic diluents in membrane preparation and thus aligns with "Less Hazardous Chemical Syntheses". Click here for more information.

Application

• Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma towards a Vitamin D susceptible state.: This groundbreaking study utilizes glyceryl triacetate as part of an epigenetic priming strategy to sensitize pancreatic ductal adenocarcinoma to Vitamin D, marking a significant advancement in cancer treatment modalities (He et al., 2024).


• Glyceryl triacetate promotes blood-brain barrier recovery after ischemic stroke through lipogenesis-mediated IL-33 in mice.: Research demonstrates glyceryl triacetate′s effectiveness in enhancing blood-brain barrier repair post-ischemic stroke via lipogenesis pathways, offering insights into novel stroke recovery treatments (Wei et al., 2023).


• Development of A Nanostructured Lipid Carrier-Based Drug Delivery Strategy for Apigenin: Experimental Design Based on CCD-RSM and Evaluation against NSCLC In Vitro.: This study details the formulation of a nanostructured lipid carrier incorporating glyceryl triacetate, optimized for delivering apigenin to combat non-small cell lung cancer, emphasizing the potential of glyceryl triacetate in targeted therapy applications (Wang et al., 2023).


• Are New Phthalate Ester Substitutes Safer than Traditional DBP and DiBP Comparative Endocrine-Disrupting Analyses on Zebrafish Using In Vivo, Transcriptome, and In Silico Approaches.: Investigating glyceryl triacetate as a safer alternative to traditional phthalate esters, this study explores its lower endocrine-disrupting effects, contributing to safer industrial and pharmaceutical applications (Tan et al., 2023).


• Glyceryl triacetate feeding in mice increases plasma acetate levels but has no anticonvulsant effects in acute electrical seizure models.: This research evaluates the biochemical impact of glyceryl triacetate on plasma acetate levels, providing valuable data on its metabolic effects despite a lack of anticonvulsant properties in specific seizure models (Xu et al., 2022).

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 10 - Combustible liquids
• wgk: WGK 1
• flash_point_f: 298.4 °F - closed cup
• flash_point_c: 148 °C - closed cup
• ppe: Eyeshields, Gloves